Lexaria Bioscience (NASDAQ:LEXX) Issues Quarterly Earnings Results

Lexaria Bioscience (NASDAQ:LEXX) released its earnings results on Monday. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01, Zacks reports. Lexaria Bioscience had a negative return on equity of 88.88% and a negative net margin of 1,473.04%.

Lexaria Bioscience Trading Up 2.6 %

Lexaria Bioscience stock traded up $0.04 during midday trading on Monday, reaching $1.39. The company’s stock had a trading volume of 15,099 shares, compared to its average volume of 172,430. The stock has a market cap of $24.31 million, a PE ratio of -2.77 and a beta of 0.86. Lexaria Bioscience has a 52 week low of $1.15 and a 52 week high of $4.44. The business has a 50-day moving average price of $1.52 and a 200-day moving average price of $2.05.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their price objective on shares of Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, January 24th.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.